



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: MAIL STOP 2600 PATENT AND TRADEMARK OFFICE  
Washington, DC 20503  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/802,376	03/09/2001	Gary Van Nest	377882001700	8397

25/26 7590 01/24/2003

MORRISON & FOERSTER LLP  
755 PAGE MILL RD  
PALO ALTO, CA 94304-1018

EXAMINER

ZARA, JANE J

ART UNIT PAPER NUMBER

1635

DATE MAILED 01/24/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.  
09/802,376

Applicant(s)  
Van Nest et al

Examiner  
Jane Zara

Art Unit  
1635



The MAILING DATE of this communication appears on the cover sheet with the correspondence address

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136. a) In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. 35 U.S.C. § 133.
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704.b.

## Status

- 1) ☒ Responsive to communication(s) filed on Nov 13, 2002
- 2a) This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-66 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claims 1-66 are subject to restriction and/or election requirement.

## Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are a) \_\_\_\_\_ accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) All b) Some\* c) None of:  
1. Certified copies of the priority documents have been received.  
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_  
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\*See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- |   |   |
|---|---|
| 1. Notice of References Cited PTO-892                     | 4. Interview Summary PTO 413, Paper No.:          |
| 2. Notice of Draftsperson's Patent Drawing Review PTO-948 | 5. Notice of Informal Patent Application PTO 152: |
| 3. Information Disclosure Statement PTO-1449, Paper No.:  | 6. Other:   |

File

Application Control Number: 09 802,376

Page 2

Art Unit: 1635

### DETAILED ACTION

This communication is in response to the communication filed November 13, 2002, Paper No. 10.

Claims 1-66 are pending in the instant application.

The restriction set forth in Paper No. 9, mailed October 3, 2002, is hereby vacated and a new restriction requirement is set forth below.

#### *Election/Restriction*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, 56-66, drawn to compositions comprising and IMP.MC complex, classified in class 435, subclass 23.1.
- II. Claims 12-55, drawn to methods of immune modulation, classified in class 514, subclass 44.

Please elect one invention from each of these patentably distinct groups: a) Solid or liquid phase microcarrier **AND** b) Covalently or non-covalently linked IMP.MC complex.

It should be noted that claims 1-66 were found to be generic to the multiple groups a) and b) listed directly above and will therefore be examined according to the limitations of the elected group. Applicants are required to amend the claims according to the subject matter of the elected group.

Art Unit: 1635

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions I and II are biologically and functionally different and distinct from each other and thus one does not render the other obvious. The compositions of Group I are not required for the methods of Group II. The operation, function and effects of the compositions of Group I are completely different and distinct from operation, function and effects of the methods of Group II. Therefore, the inventions of these different, distinct groups are capable of supporting separate patents.

Inventions of the different groups within Group I (i.e. combination of Ia, Ib) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions encompassed within the generic Groups Ia, Ib are chemically, biologically, structurally, and functionally distinct from each other and thus one does not render the other obvious. The liquid phase microcarrier is not required to produce the solid phase microcarrier, nor vice versa and the covalently linked IMP:MC complex is not required to produce the non-covalently linked IMP:MC complex and vice versa. Therefore the inventions of these different and distinct groups are capable of supporting separate patents.

Art Unit: 1635

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Art Unit: 1635

***Conclusion***

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(703) 306-5820**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (703) 308-0447. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (703) 305-3413. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



**RAM R. SHUKLA, PH.D**  
**PATENT EXAMINER**

**JZ**

January 22, 2003